Cas9-AAV6-engineered human mesenchymal stromal cells improved cutaneous wound healing in diabetic mice

Waracharee Srifa; Nina Kosaric; Alvaro Amorin; Othmane Jadi; Yujin Park; Sruthi Mantri; Joab Camarena; Geoffrey C. Gurtner; Matthew Porteus

doi:10.1038/s41467-020-16065-3

Nature Communications (May 2020)

Cas9-AAV6-engineered human mesenchymal stromal cells improved cutaneous wound healing in diabetic mice

Waracharee Srifa,
Nina Kosaric,
Alvaro Amorin,
Othmane Jadi,
Yujin Park,
Sruthi Mantri,
Joab Camarena,
Geoffrey C. Gurtner,
Matthew Porteus

Affiliations

Waracharee Srifa: Department of Pediatrics, Stanford University School of Medicine
Nina Kosaric: Program in Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine
Alvaro Amorin: Department of Pediatrics, Stanford University School of Medicine
Othmane Jadi: Department of Pediatrics, Stanford University School of Medicine
Yujin Park: Department of Surgery, Stanford University School of Medicine
Sruthi Mantri: Department of Pediatrics, Stanford University School of Medicine
Joab Camarena: Department of Pediatrics, Stanford University School of Medicine
Geoffrey C. Gurtner: Department of Surgery, Stanford University School of Medicine
Matthew Porteus: Department of Pediatrics, Stanford University School of Medicine

DOI: https://doi.org/10.1038/s41467-020-16065-3
Journal volume & issue: Vol. 11, no. 1
pp. 1 – 14

Abstract

Read online

Human mesenchymal stromal cells are a promising source for cell-based therapies. Here the authors use Cas9 to engineer lines that secrete PDGF-BB and VEFGA for improving wound healing.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal